Compare iShares Bitcoin Trust (IBIT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Moderna, Inc. — how do they compare? iShares Bitcoin Trust trades at $47.16 (market cap $67.31B), while Moderna, Inc. trades at $197.19 (market cap $78.65B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Moderna, Inc. for 59 Days on average.
| IBIT | MRNA | |
|---|---|---|
Market Cap | $67.31B | $78.65B |
Volume | 56,154,544 | 37,373,437 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $203.46 |
52-Week Low | $33.29 | $22.36 |
Typical Hold Time | 40 Days | 59 Days |
Enterprise Value | — | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.21, down 2.64% on the day, with technical indicators showing a bullish overall signal. The stock faces immediate support at $47 and resistance at $48. Recent news highlights significant institutional interest, with BlackRock's IBIT recording $196 million in daily inflows according to 24/7 Wall Street on October 4, 2026.
The outlook remains positive with strong institutional inflows and technical momentum, though the absence of traditional financial metrics requires careful evaluation. Key risks include market volatility and dependency on Bitcoin ETF performance, while analyst sentiment appears cautiously optimistic based on recent fund flow trends.
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
